Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Applied BioCode Licenses its Barcoded Magnetic Bead Technology to Genetic Analysis

Published: Wednesday, January 08, 2014
Last Updated: Wednesday, January 08, 2014
Bookmark and Share
License and supply agreement for multiplex molecular diagnostic testing of microbial imbalances in the GI tract.

Applied BioCode has announced that it has signed a License and Supply Agreement for its Barcoded Magnetic Bead (BMB) technology with Genetic Analysis of Oslo, Norway.

The license from Applied BioCode will give Genetic Analysis access to specific Applied BioCode BMB patents and BioCode analyzers for Molecular Diagnostic testing of microbial imbalances in the GI tract.

The license covers both In-Vitro Diagnostic and Life Science Research applications in this area. Genetic Analysis launched their first product, the GA-map™ IBS Dysbiosis Test, at the United European Gastroenterology Week (UEGW) Meeting in Berlin, Germany in October 2013.

Genetic Analysis CEO Kari Stenersen explained that “Numerous studies have suggested the role of gut microbiota in Irritable Bowel Syndrome (IBS). However, it is only recently that links between dysbiosis (imbalance in microbiota) and IBS have been explored. Working with leading experts in Scandinavia and Europe, we initiated a series of studies in order to document the use of the GA-map™ IBS Dysbiosis Test in various IBS patient populations. We found that Dysbiosis frequency in IBS patients ranged from 35-77% between the clinics. On average, 67% of the IBS patients experienced dysbiosis. The trials have now been extended with feedback from participating investigators backing our decision to bring GA-map™ IBS Dysbiosis Test to market.” The GA-map™ IBS Dysbiosis Test can be run in any accredited molecular diagnostics laboratory.

“We are very pleased to partner with Genetic Analysis in this important and growing area of the market” said Winston Ho, President of Applied BioCode.

Ho continued, “Our Barcoded Magnetic Beads and BioCode multiplex analyzers along with Genetic Analysis’s GA-map™ IBS Dysbiosis Test will enable researchers and healthcare providers access to new ways to address this sometime debilitating disease.”

Further terms of the strategic partnership and license agreement were not immediately available.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Applied BioCode, Diatherix Ink Partnership
Applied BioCode announced that it has signed a Partnership and Supply Agreement with Diatherix Laboratories, LLC, a Eurofins company.
Friday, June 17, 2016
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Smartphone Laboratory Detects Cancer
Researchers develop low-cost, portable laboratory on a smartphonecapable of analysing multiple samples simultaneously.
Nanomedicine for Breast Cancer Treatment
Using nanoparticles measuring only billionths of a meter in size, doctors are able to deliver drug molecules directly to the affected tissue.
Clamping Down on Biomolecules
Physicists have developed a novel nanotool that provides a means of characterizing the mechanical properties of biomolecules.
MRIs for Fetal Health
Algorithm could help analyze fetal scans to determine whether interventions are warranted.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Supercomputers Could Improve Cancer Diagnostics
Researchers push the boundaries of cancer research through high-performance computing to map the human immunone.
Transgenomic, Precipio Diagnostics Merger
Merger will creates a robust diagnostic platform focused on improving accuracy of cancer diagnoses.
Inflammation Test May Predict Cardiovascular Disease
An assessment combining measures of immune-cell responsiveness predicted cardiovascular problems in individuals who likely would have slipped under the radar.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos